Get the Stockscreener App
64.87
1.01%
0.65
After Hours:
64.87
Ani Pharmaceuticals Inc Stock (ANIP) Latest News
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN
ANI Pharmaceuticals launches generic Nitazoxanide Tablets By Investing.com - Investing.com South Africa
ANI Pharmaceuticals Launches Kionex Suspension For Electrolyte Imbalance Management: Key Trend Transforming... - WhaTech
Ani Pharmaceuticals Launches Nitazoxanide Tablets for Treating Diarrhea -March 19, 2025 at 09:33 am EDT - Marketscreener.com
ANI Pharmaceuticals launches generic Nitazoxanide Tablets - Investing.com
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets - The Manila Times
ANI Pharmaceuticals Announces The Launch Of Nitazoxanide Tablets -March 19, 2025 at 06:51 am EDT - Marketscreener.com
Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan
ANI Pharmaceuticals settles royalty obligation for $17.25 million By Investing.com - Investing.com Australia
ANI Pharmaceuticals Eliminates Royalty Obligation On ILUVIEN And YUTIQ - Nasdaq
ANI Pharma buys Iluvien and Yutiq royalties (ANIP:NASDAQ) - Seeking Alpha
ANI Pharma buys royalties linked to Iluvien and Yutiq - MSN
ANI Pharmaceuticals Completes Buyout of Royalty Obligation for Iluvien, Yutiq -March 18, 2025 at 08:20 am EDT - Marketscreener.com
ANI Pharmaceuticals settles royalty obligation for $17.25 million - Investing.com
ANI Pharmaceuticals Completes $17.25 Million Buyout of Royalty Obligation for ILUVIEN and YUTIQ - Nasdaq
ANI Pharmaceuticals Announces Buyout Of Royalty Obligation For Iluvien And Yutiq -March 18, 2025 at 06:55 am EDT - Marketscreener.com
ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ® - GlobeNewswire
ANI Pharma's Strategic $17M Move Boosts Profit Potential for Eye Drug Portfolio - StockTitan
Jefferies Initiates Coverage of ANI Pharmaceuticals (ANIP) with Buy Recommendation - Nasdaq
Ani Pharmaceuticals sr. VP Cook sells $25,332 in stock - Investing.com India
Ani Pharmaceuticals sr. VP Cook sells $25,332 in stock By Investing.com - Investing.com South Africa
Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts - Benzinga
ANI Pharma rises on expanded US approval for eye-disease drug - TradingView
Jefferies Initiates Coverage on ANI Pharmaceuticals With Buy Rating, $80 Price Target - Marketscreener.com
ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label - GlobeNewswire
ILUVIEN Scores Major FDA Win: Now Treats Two Serious Eye Conditions - StockTitan
JPMorgan Chase & Co. Begins Coverage on ANI Pharmaceuticals (NASDAQ:ANIP) - Defense World
ANI Pharma wins Overweight rating at J.P. Morgan on growth prospects - MSN
ANI Pharma stock wins J.P. Morgan bullish view (ANIP:NASDAQ) - Seeking Alpha
Exploring Growth Opportunities: Raytheon, ANI Pharmaceuticals, DeckersNews and Statistics - IndexBox, Inc.
Zacks.com featured highlights include ANI Pharmaceuticals, Dana, Pitney Bowes, Priority Technology and Kingstone - Yahoo Finance
JPMorgan Initiates ANI Pharmaceuticals at Overweight With $85 Price Target -March 12, 2025 at 07:10 am EDT - Marketscreener.com
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Recommendation of “Buy” by Analysts - Defense World
ANI Pharmaceuticals at Leerink Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
ANI Pharmaceuticals Discusses Alimera Acquisition Challenges - TipRanks
Ani Pharmaceuticals’ chief HR officer Krista Davis sells $60,860 in stock - Investing.com Canada
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2024 Earnings Call Transcript - MSN
Don't Ignore The Insider Selling In ANI Pharmaceuticals - Simply Wall St
Top Executive at ANI Pharmaceuticals Sells Thousands in Stock! - TipRanks
Ani Pharmaceuticals SVP sells $323,049 in stock By Investing.com - Investing.com UK
ANI Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis - MarketBeat
Q1 Earnings Estimate for ANIP Issued By HC Wainwright - Defense World
ANI Pharma at Raymond James Conference: Strategic Shift to Rare Diseases - Investing.com Canada
Ani Pharmaceuticals’ Future Hinges on Ocumension’s Success with ILUVIEN in Asia-Pacific - MSN
Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? - Nasdaq
Rhumbline Advisers Trims Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
Principal Financial Group Inc. Acquires 3,816 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
ANI Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
ANI Pharmaceuticals (NASDAQ:ANIP) Downgraded by StockNews.com to Sell - Defense World
ANI Pharmaceuticals (NASDAQ:ANIP) Given Buy Rating at HC Wainwright - Defense World
ANI Pharmaceuticals Reports Record 2024 Results and Raises 2025 Guidance - TipRanks
ANI Pharmaceuticals Gets FDA Approval for Cortrophin Gel in Prefilled Syringe Format as MS Therapy - Marketscreener.com
ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe - Marketscreener.com
ANI Pharmaceuticals Expands Treatment Options: FDA Greenlights Cortrophin Gel Prefilled Syringes - StockTitan
Truist maintains hold on ANI Pharmaceuticals, keeps $62 target - Investing.com India
ANI Pharmaceuticals Inc (ANIP) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance - GlobeNewswire
0.19%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):